NeOnc Technologies Holdings Inc

NeOnc Technologies (Nasdaq: NTHI) CEO Amir Heshmatpour continues to deepen his alignment with shareholders, investing nearly $1M of personal capital over the past year — including $500K+ in recent open-market purchases. This comes at a pivotal moment for NeOnc, as the company advances toward key clinical and regulatory milestones. Read the full press release. investors.neonc.com/news-releases/… #NeOnc #NTHI #Biotech #Healthcare #Investing #BrainCancerResearch

NeOnc Technologies $NTHI recently announced approximately $300,000 in open-market stock purchases by Chairman & CEO Amir Heshmatpour, reinforcing management’s alignment with shareholders and confidence in the Company’s long-term strategy. investors.neonc.com/news-releases/…

NeOnc Technologies | One Year on NASDAQ (NTHI) | Progress, Pipeline & What’s Next One year after NeOnc Technologies' listing on NASDAQ under the ticker NTHI, NeOnc reflects on key clinical and regulatory milestones achieved as a public company. This video highlights progress across the pipeline, reinforces the company’s strategic positioning, and looks ahead to the next phase of execution, bringing innovative therapies closer to patients who need them most. youtube.com/watch?v=uxcjTk… #NTHI #NeOnc #GBM

NeOnc Technologies Holdings Inc NTHI will host a live investor conference call and webcast on March 4, 2026 at 6:00 a.m. PT / 9:00 a.m. ET to present initial data from the Phase 1 dose-escalation portion of the NEO212-01 Phase 1/2 clinical trial. The discussion will include: • Safety and toxicity findings • Dose-escalation observations • Pharmacokinetic data • Planned regulatory next steps 📅 March 4, 2026 ⏰ 6:00 a.m. PT / 9:00 a.m. ET 🔗 Live webcast: webcaster5.com/Webcast/Page/3… We look forward to sharing these important clinical updates with the investment community. investors.neonc.com/news-releases/…

Top Entrepreneurs Going into 2026 via @USATODAY We’re thrilled to celebrate our CEO, Amir Heshmatpour, being featured in USA Today’s list of Top Entrepreneurs Going Into 2026 — a testament to visionary leadership and bold innovation shaping the future of biotech. 👏 Congratulations, to Amir & NeOnc! Here’s to a year of breakthrough science, meaningful progress, and continued impact for patients worldwide. #Leadership #Entrepreneurship #Biotech #Innovation #2026Vision #Neonc usatoday.com/story/special/…

NeOnc has secured a strategic PIPE investment led by a $10M commitment from Cinctive Capital Management, with total gross proceeds expected to reach ~$16M. This investment reflects strong institutional confidence in NeOnc’s mission, science, and proprietary CNS delivery platforms. It supports the acceleration of clinical programs focused on bypassing the blood-brain barrier to treat CNS cancers. #NeOnc #NTHI #CNSCancer #BiotechInvesting #ClinicalTrials investors.neonc.com/news-releases/…

This video highlights pediatric DIPG patients in China receiving investigational NEO100-03 intranasal therapy following prior standard treatments. Their stories underscore the urgent unmet need in pediatric brain cancer and the importance of continued clinical research. #NeOnc #PediatricCancer #BrainCancerResearch #DIPG #ClinicalResearch

Updated clinical data for intranasal NEO100 show continued durable responses in recurrent IDH1-mutant astrocytoma 🧠 • 24% radiographic remission • 44% PFS-6 • 36% alive ≥18 months • No significant toxicity A promising step forward for patients with limited options. Read the full press release below: investors.neonc.com/news-releases/…

NeOnc Technologies (Nasdaq: $NTHI) announces new findings showing that ultrasound enhances the potency of NEO100 in treating primary and metastatic brain tumors. A breakthrough at the intersection of AI, oncology, and precision medicine. #NTHI #AIinMedicine #Biotech #CancerResearch #NeOnc #NEO100 investors.neonc.com/news-releases/…

🚨 NeOnc completes enrollment in its pivotal NEO100 Phase 2a trial for IDH1-mutant recurrent glioma. Preliminary data coming Q2 2026. This milestone follows positive results from a 24-patient cohort shared on the Nov. 12 investor call. investors.neonc.com/news-releases/… #NTHI #NEO100 #Biotech #Glioma #CNS

NeOnc Technologies (NTHI) is honored to announce that His Highness Sheikh Nahyan bin Zayed Al Nahyan has assumed the role of Executive Chairman of NuroMENA, our Middle East subsidiary — marking a new era in UAE–US collaboration against brain cancer. 🇦🇪🇺🇸🧠 investors.neonc.com/news-releases/…

As a Director of the biotech company @NeOncTechInc bringing brain cancer treatments to market, this independent analysis is spot on: (1) "NeOnc is at a key inflection point from a survival story to a growth story" Kudos to the team! seekingalpha.com/article/482891…

The brain has a natural barrier that blocks most drugs from reaching where they are needed. @NeOncTechInc is changing that. If you missed this episode, you can watch it now at HealthUncensoredTV.com. Follow us and @drdrew to stay on top of everything health.

We’re going on @HUwithDrDrew! 🎉 📅 Sept 25 | ⏰ Airs nationwide at 8 AM| Lifetime TV Hear from Dr. Chen (Founder & CEO) & Amir Heshmatpour (President & Executive Chairman) about how @NeOncTechInc is redefining brain cancer treatment. Plus, Adeline, a remarkable NEO-100 patient, will share her inspiring journey and the impact of NeOnc’s therapies. 📺 Tune in for a powerful conversation of science, hope, and innovation. #NeOnc #DrDrew #HealthUncensoredwithdrdrew #BrainCancer #CancerCare #Innovation #GBM

We’re excited to be part of the American Brain Tumor Association 2025 National Conference! 💡 At @NeOncTechInc, we’re driven by innovation and the belief that together we can create better outcomes for patients and their families. 📍 Stop by and visit us at the event! #BTSM #braintumor #braincancer #GBM #Glioblastoma #GlioblastomaAwareness #Meningioma #BrainMets #clinicaltrials #ABTANationalConference2025 #BrainTumorStrong #PatientSupport

In the latest episode of Trader Talk @YahooFinance , I speak with Amir Heshmatpour, executive chairman and president of NeOnc Technologies $NTHI. Amir explains NeOnc’s focus on intranasal drug delivery for brain cancer, the significance of its partnership with USC’s medical school, and how global clinical trials are expanding the company’s reach. It’s a rare behind-the-scenes look at how a small-cap biotech is executing on a global stage. finance.yahoo.com/video/ai-biote…

💡 Innovating Treatment. Improving Lives. At NeOnc Technologies, we’re pushing boundaries with intranasal therapies that overcome the blood-brain barrier—targeting brain tumors like GBM, meningioma, and high-grade gliomas. ⁠ 🔬 Now enrolling for clinical trials: • NEO100 for GBM, meningioma, and pediatric glioma • NEO212 for brain metastasis neonc.com/clinical-studi… #GBM #NBTS #BTSM #clinicaltrials #braintumor #braincancer #Meningioma #BrainMets @theABTA @NeOncTechInc

Dr. Thomas Chen, Founder of NeOnc Technologies Holdings Inc., discusses our mission to innovate brain cancer treatment and bring new hope to patients. From pioneering intranasal drug delivery systems to advancing clinical research, NeOnc is committed to transforming healthcare and improving patient outcomes. Don’t miss the chance to hear Dr. Chen share what NeOnc values and what we are fighting for! #NeOnc #BrainCancer #HealthcareInnovation #Biotech #PatientCare #Leadership #NeOnc #NTHI NasdaqInc./ Vanja Savic

A historic moment for NeOnc Technologies Holdings Inc.! 🎉 Our Executive Chairman, Amir Heshmatpour, and CEO, Dr. Thomas Chen, had the honor of ringing the opening bell at Nasdaq. This marks a significant milestone for the company and reflects our growth and commitment to innovation in the industry. Don’t miss the chance to hear Amir Heshmatpour share NeOnc’s mission and vision for the future! Watch the full video below: #NeOnc #Nasdaq #OpeningBell #BrainCancer #BiotechInnovation #HealthcareLeadership Nasdaq, Inc./ Vanja Savic